Cargando…
Prognostic Factors for Overall Survival in Patients with HCV-Related HCC Undergoing Molecular Targeted Therapies: Beyond a Sustained Virological Response
SIMPLE SUMMARY: The eradication of the hepatitis C virus (HCV) has had a significant impact on the management of patients with HCV-related hepatocellular carcinoma (HCC). However, its eradication has not completely resolved survival issues in patients with HCV-related HCC. Therefore, the present stu...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562238/ https://www.ncbi.nlm.nih.gov/pubmed/36230773 http://dx.doi.org/10.3390/cancers14194850 |
_version_ | 1784808126538579968 |
---|---|
author | Minami, Yasunori Aoki, Tomoko Chishina, Hirokazu Takita, Masahiro Hagiwara, Satoru Ida, Hiroshi Ueshima, Kazuomi Nishida, Naoshi Kudo, Masatoshi |
author_facet | Minami, Yasunori Aoki, Tomoko Chishina, Hirokazu Takita, Masahiro Hagiwara, Satoru Ida, Hiroshi Ueshima, Kazuomi Nishida, Naoshi Kudo, Masatoshi |
author_sort | Minami, Yasunori |
collection | PubMed |
description | SIMPLE SUMMARY: The eradication of the hepatitis C virus (HCV) has had a significant impact on the management of patients with HCV-related hepatocellular carcinoma (HCC). However, its eradication has not completely resolved survival issues in patients with HCV-related HCC. Therefore, the present study investigated prognostic factors for survival in patients with HCV-related HCC undergoing molecular targeted therapies. In total, 359 HCC patients treated with first-line chemotherapy were enrolled. The median follow-up duration was 16.0 months (range, 1.0–115.7) and the median duration of first-line systemic therapy was 3.7 months (range, 0.7–86.9). The achievement of a sustained virological response (SVR) (p < 0.001), albumin-bilirubin (ALBI) grade II/III (p < 0.001), Barcelona Clinic Liver Cancer (BCLC) stage C (p = 0.005), extrahepatic spread (p < 0.001), baseline AFP level ≥ 90 (p = 0.038), baseline DCP level ≥ 500 (p < 0.001), and a fibrosis-4 (FIB-4) index ≥ 4 (p = 0.003) were identified as independent prognostic factors for overall survival. ABSTRACT: Background: The treatment of the hepatitis C virus (HCV) has reduced the risk of hepatocellular carcinoma (HCC)-related mortality. Many patients with advanced HCC have achieved longer survival through systemic chemotherapy. However, survivors of HCC may develop liver cancer during and after treatment. Therefore, the present study investigated prognostic factors for survival in patients with HCV-related HCC in the new era of molecular targeted therapy. Methods: A total of 359 patients with HCV-related HCC treated with first-line chemotherapy were reviewed. A Cox proportional hazards model and Kaplan–Meier curve were used to identify prognostic factors associated with survival outcomes. Results: The median follow-up duration was 16.0 months (range, 1.0–115.7) and the median duration of first-line systemic therapy was 3.73 months (range, 0.7–86.9). The achievement of a sustained virological response (SVR) (p < 0.001), albumin–bilirubin (ALBI) grade II/III (p < 0.001), Barcelona Clinic Liver Cancer (BCLC) stage C (p = 0.005), extrahepatic spread (p < 0.001), baseline AFP (alpha-fetoprotein) level ≥ 90 (p = 0.038), baseline DCP (des-γ-carboxy prothrombin) level ≥ 500 (p < 0.001), and a fibrosis-4 (FIB-4) index ≥ 4 (p = 0.003) were identified as prognostic factors for overall survival. Conclusions: The achievement of SVR was most strongly associated with overall survival. Other factors, such as the BCLC stage, extrahepatic spread, baseline tumor marker (AFP/DCP) levels, ALBI grade, and FIB-4 index need to be considered in the management of patients with HCV-related HCC. |
format | Online Article Text |
id | pubmed-9562238 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95622382022-10-15 Prognostic Factors for Overall Survival in Patients with HCV-Related HCC Undergoing Molecular Targeted Therapies: Beyond a Sustained Virological Response Minami, Yasunori Aoki, Tomoko Chishina, Hirokazu Takita, Masahiro Hagiwara, Satoru Ida, Hiroshi Ueshima, Kazuomi Nishida, Naoshi Kudo, Masatoshi Cancers (Basel) Article SIMPLE SUMMARY: The eradication of the hepatitis C virus (HCV) has had a significant impact on the management of patients with HCV-related hepatocellular carcinoma (HCC). However, its eradication has not completely resolved survival issues in patients with HCV-related HCC. Therefore, the present study investigated prognostic factors for survival in patients with HCV-related HCC undergoing molecular targeted therapies. In total, 359 HCC patients treated with first-line chemotherapy were enrolled. The median follow-up duration was 16.0 months (range, 1.0–115.7) and the median duration of first-line systemic therapy was 3.7 months (range, 0.7–86.9). The achievement of a sustained virological response (SVR) (p < 0.001), albumin-bilirubin (ALBI) grade II/III (p < 0.001), Barcelona Clinic Liver Cancer (BCLC) stage C (p = 0.005), extrahepatic spread (p < 0.001), baseline AFP level ≥ 90 (p = 0.038), baseline DCP level ≥ 500 (p < 0.001), and a fibrosis-4 (FIB-4) index ≥ 4 (p = 0.003) were identified as independent prognostic factors for overall survival. ABSTRACT: Background: The treatment of the hepatitis C virus (HCV) has reduced the risk of hepatocellular carcinoma (HCC)-related mortality. Many patients with advanced HCC have achieved longer survival through systemic chemotherapy. However, survivors of HCC may develop liver cancer during and after treatment. Therefore, the present study investigated prognostic factors for survival in patients with HCV-related HCC in the new era of molecular targeted therapy. Methods: A total of 359 patients with HCV-related HCC treated with first-line chemotherapy were reviewed. A Cox proportional hazards model and Kaplan–Meier curve were used to identify prognostic factors associated with survival outcomes. Results: The median follow-up duration was 16.0 months (range, 1.0–115.7) and the median duration of first-line systemic therapy was 3.73 months (range, 0.7–86.9). The achievement of a sustained virological response (SVR) (p < 0.001), albumin–bilirubin (ALBI) grade II/III (p < 0.001), Barcelona Clinic Liver Cancer (BCLC) stage C (p = 0.005), extrahepatic spread (p < 0.001), baseline AFP (alpha-fetoprotein) level ≥ 90 (p = 0.038), baseline DCP (des-γ-carboxy prothrombin) level ≥ 500 (p < 0.001), and a fibrosis-4 (FIB-4) index ≥ 4 (p = 0.003) were identified as prognostic factors for overall survival. Conclusions: The achievement of SVR was most strongly associated with overall survival. Other factors, such as the BCLC stage, extrahepatic spread, baseline tumor marker (AFP/DCP) levels, ALBI grade, and FIB-4 index need to be considered in the management of patients with HCV-related HCC. MDPI 2022-10-04 /pmc/articles/PMC9562238/ /pubmed/36230773 http://dx.doi.org/10.3390/cancers14194850 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Minami, Yasunori Aoki, Tomoko Chishina, Hirokazu Takita, Masahiro Hagiwara, Satoru Ida, Hiroshi Ueshima, Kazuomi Nishida, Naoshi Kudo, Masatoshi Prognostic Factors for Overall Survival in Patients with HCV-Related HCC Undergoing Molecular Targeted Therapies: Beyond a Sustained Virological Response |
title | Prognostic Factors for Overall Survival in Patients with HCV-Related HCC Undergoing Molecular Targeted Therapies: Beyond a Sustained Virological Response |
title_full | Prognostic Factors for Overall Survival in Patients with HCV-Related HCC Undergoing Molecular Targeted Therapies: Beyond a Sustained Virological Response |
title_fullStr | Prognostic Factors for Overall Survival in Patients with HCV-Related HCC Undergoing Molecular Targeted Therapies: Beyond a Sustained Virological Response |
title_full_unstemmed | Prognostic Factors for Overall Survival in Patients with HCV-Related HCC Undergoing Molecular Targeted Therapies: Beyond a Sustained Virological Response |
title_short | Prognostic Factors for Overall Survival in Patients with HCV-Related HCC Undergoing Molecular Targeted Therapies: Beyond a Sustained Virological Response |
title_sort | prognostic factors for overall survival in patients with hcv-related hcc undergoing molecular targeted therapies: beyond a sustained virological response |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562238/ https://www.ncbi.nlm.nih.gov/pubmed/36230773 http://dx.doi.org/10.3390/cancers14194850 |
work_keys_str_mv | AT minamiyasunori prognosticfactorsforoverallsurvivalinpatientswithhcvrelatedhccundergoingmoleculartargetedtherapiesbeyondasustainedvirologicalresponse AT aokitomoko prognosticfactorsforoverallsurvivalinpatientswithhcvrelatedhccundergoingmoleculartargetedtherapiesbeyondasustainedvirologicalresponse AT chishinahirokazu prognosticfactorsforoverallsurvivalinpatientswithhcvrelatedhccundergoingmoleculartargetedtherapiesbeyondasustainedvirologicalresponse AT takitamasahiro prognosticfactorsforoverallsurvivalinpatientswithhcvrelatedhccundergoingmoleculartargetedtherapiesbeyondasustainedvirologicalresponse AT hagiwarasatoru prognosticfactorsforoverallsurvivalinpatientswithhcvrelatedhccundergoingmoleculartargetedtherapiesbeyondasustainedvirologicalresponse AT idahiroshi prognosticfactorsforoverallsurvivalinpatientswithhcvrelatedhccundergoingmoleculartargetedtherapiesbeyondasustainedvirologicalresponse AT ueshimakazuomi prognosticfactorsforoverallsurvivalinpatientswithhcvrelatedhccundergoingmoleculartargetedtherapiesbeyondasustainedvirologicalresponse AT nishidanaoshi prognosticfactorsforoverallsurvivalinpatientswithhcvrelatedhccundergoingmoleculartargetedtherapiesbeyondasustainedvirologicalresponse AT kudomasatoshi prognosticfactorsforoverallsurvivalinpatientswithhcvrelatedhccundergoingmoleculartargetedtherapiesbeyondasustainedvirologicalresponse |